Twitxy
Saved
@NicholasShortMD's profile picture
View on X

Nicholas Short MD

@NicholasShortMD

Associate Professor, Department of Leukemia, MD Anderson Cancer Center - Research interest: phase I/II clinical trials in AML and ALL, developing new MRD assays
Houston, TX faculty.mdanderson.org/profiles/nicho… Joined February 2017
181 Following 2.2K Followers 351 Posts

Latest posts 5

Nicholas Short MD @NicholasShortMD
Very nice of @AjHematology to add a wonderful visual abstract to accompany our review article on MRD in AML. Link here: onlinelibrary.wiley.com/doi/10.1002/aj…
@DillonHaem
onlinelibrary.wiley.com Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new... Answer questions and earn CME credit
Hagop Kantarjian,MD @DrHKantarjian Sep 25, 2024
MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology
doi.org/10.1002/ajh.27…
#leusm
View quoted post on X
4 replies 15 reposts 80 likes 8.1K views View on X
Nicholas Short MD @NicholasShortMD
Happy to see our trial of DAC, venetoclax and ponatinib for advanced phase CML published in @TheLancetHaem. Response rate was 80%, allowing for bridge to alloSCT. Still a lot more work to be done in this rare disease. We have new TKI combo studies now open and enrolling.
UT MD Anderson Verified account @UTMDAnderson Sep 18, 2024
In a Phase II trial led by Dr. Nicholas Short, 80% of patients with previously untreated chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia achieved remission with a novel treatment combination: bit.ly/4eaCHh0 @NicholasShortMD #EndCancer
View quoted post on X
4 replies 10 reposts 69 likes 6.7K views View on X
Nicholas Short MD @NicholasShortMD
Our new review on inotuzumab ozogamicin is now online. We cover the clinical development of INO, pivotal studies, and the novel uses of INO in B-ALL, including combination therapies and use in the frontline setting.
Hagop Kantarjian,MD @DrHKantarjian May 13, 2024
Inotuzumab approved as monotherapy for R/R #ALL but new research is expanding its use into frontline, for MRD+, and in combo with blinatumomab. Best outcomes seen in combinations.
@NicholasShortMD of @MDAndersonNews #Leukemia
jhoonline.biomedcentral.com/articles/10.11…
#leusm
View quoted post on X
3 replies 0 reposts 29 likes 2.7K views View on X
Nicholas Short MD @NicholasShortMD
Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at @JCO_ASCO
In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven)
Could be delivered safely with appropriate dose modifications.
ascopubs.org/doi/10.1200/JC…
ascopubs.org Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Muta... PURPOSEAzacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, FLT3 mutations are a common mechanism of resistance...
Hagop Kantarjian,MD @DrHKantarjian Jan 29, 2024
Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population.
@NicholasShortMD of @MDAndersonNews #Leukemia
ascopubs.org/doi/10.1200/JC… @JCO_ASCO
#leusm
View quoted post on X
4 replies 22 reposts 93 likes 12K views View on X